Qaytarish

NT-proBNP (B-tur natriuretik peptidning N-terminal propeptidi)

Kod:13004|CPT:83880|LOINC:33762-6

Sinonimlar
Мозговой натрийуретический пропептидN-терминальный фрагмент мозгового натрийуретического пептидаN-терминальный промозговой натрийуретический пептидN-концевой пропептид натрийуретического гормона (В-типа)B-type natriuretic peptideBrain natriuretic peptideBrain natriuretic propeptideN-terminal fragment of brain natriuretic peptideN-terminal pro–B-type natriuretic peptideN-terminal proBNPN-terminal propeptide of B-type natriuretic hormoneNT-proBNPPropeptide of brain natriuretic peptideproBNP
KabiNT-proBNP

Tahlil ma'lumotlari

Tadqiqot usuli

  • Elektrokimyoluminessent immunoanaliz (ECLIA)
  • Immunoxromatografiya

Kutilayotgan natija topshirish vaqti

1 kun

Maxsus tayyorlik

  • Maintain a 12-hour fast before the specimen is collected.
  • Avoid vigorous physical activity and minimize emotional stress for at least 30 minutes prior to collection.
  • Do not smoke during the 30 minutes preceding collection.
  • Review biotin supplementation; discontinue high-dose biotin for a minimum of 72 hours before specimen collection.

Qanday foydalanish

NT-proBNP (B-tur natriuretik peptidning N-terminal propeptidi; proBNP) testi taxmin qilinayotgan yurak yetishmovchiligi tashxisini qo‘llab-quvvatlash va dispnoening kardial va pulmonar etiologiyalarini farqlashga yordam berish uchun qo‘llaniladi. U yurak yetishmovchiligining og‘irlik darajasini baholashda va vaqt davomida davolashga javobni monitoring qilishda yordam beradi. NT-proBNP, shuningdek, o‘tkir koronar sindrom va surunkali yurak yetishmovchiligida xavf stratifikatsiyasini qo‘llab-quvvatlaydi. Barqaror koronar arteriya kasalligi bo‘lgan, yurak yetishmovchiligi xavfi mavjud bemorlarda natijalar kardiovaskulyar hodisalar va o‘lim ehtimolini baholashga yordam berishi mumkin.

Cheklovlar

Qorincha miyotsitlari proBNP ni sintez qiladi; u biologik faol B-tur natriuretik peptid (BNP) va faol bo‘lmagan NT-proBNP fragmentiga parchalanadi. Bosim yoki hajm bilan ortiqcha yuklanish tufayli qorincha devorining zo‘riqishi oshishi har ikki peptidning ajralishini rag‘batlantiradi; ular o‘z navbatida natriyurez va diurezni kuchaytiradi. NT-proBNP konsentratsiyalarini klinik topilmalar va boshqa kardiovaskulyar xavf omillari bilan birga talqin qilish zarur. Qiymatlar hamroh kardial, pulmonar yoki buyrak kasalliklari mavjudida yuqoriroq bo‘lishi mumkin, va yurak yetishmovchiligi uchun diagnostik samaradorlik atrial fibrillyatsiya va sepsisda pasayadi; klinik korrelyatsiya muhim.

O'lchov birligipg/mL
Referens oraliq
YoshMinMaks
≤50y300450
50y–79y300900
79y–104y3001800
Ko'rsatmalarAssessment of patients with possible heart failure, Risk stratification in the context of acute coronary syndromes, Monitoring the effectiveness of therapy for heart failure

Natija og'ishlarining mumkin sabablari

Oshgan daraja

  • advanced age
  • atrial fibrillation
  • cardiac disease
  • chronic kidney disease
  • female sex
  • pulmonary disease
  • sepsis

Pasaygan daraja

  • biotin (high-dose)

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm1 mL (min 0.7 mL)
Saqlash tayyorlikXona harorati, Sovutilgan, Muzlatilgan

References

Elecsys proBNP II [package insert]. Indianapolis, IN: Roche Diagnostics; 2018, V1.0 English.

McCullough PA, Kluger AY. Interpreting the Wide Range of NT-proBNP Concentrations in Clinical Decision Making. J Am Coll Cardiol. 2018 Mar 20;71(11):1201-1203. PubMed 29544602

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. PubMed 34447992